This symposium is not accredited for Royal College MOC credit.
Description:
Achondroplasia is an autosomal dominant skeletal dysplasia characterized by disproportionate short stature and associated complications such as motor delay, obstructive sleep apnea, recurrent otitis media, and bowing of the lower limbs. There is an elevated risk of sudden death during infancy, primarily due to foramen magnum stenosis. Management has traditionally relied on a multidisciplinary team approach to monitor and address the evolving needs of the child throughout development. Vosoritide is the only FDA approved therapy for use in individuals with achondroplasia starting from birth. In addition, several investigational therapies are undergoing evaluation in Phase 2 and 3 clinical trials. The overarching goal of treatment is to reduce morbidity and mortality while enhancing quality of life for affected individuals.
Objectives
At the end of the session, participants will be able to:
- Cite the epidemiology and diagnostic criteria for achondroplasia.
- Restate the molecular mechanism involved in achondroplasia.
- Critique the Clinical Trial Updates on achondroplasia.
- Describe the impact of Vosoritide treatment on achondroplasia.
Speaker: Dr. Peter Kannu
Event Timeslots (1)
Day 3
-
KC 303 - Dr. Peter Kannu - Unaccredited for Royal College MOC credit
